Last October, the article 'Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity' describing identification of a potent inhibitor of the unfolded protein response (UPR) regulating potential anticancer target IRE1α was published.

Substitution of the amino-quinazoline moiety in initial clinical candidate to amino-thienopyrimidine (“Compound 25”) shows more than the 1000-fold decrease in BRaf activity with the same good IRE1α cellular potency.

“Compound 25” contains thieno[3,2-d]pyrimidine moiety in its backbone. We have made a set of in-stock compounds, which have such part – the perfect start for your research!